EuBiologics Co., Ltd. (206650.KQ)
- Previous Close
13,270.00 - Open
13,420.00 - Bid 13,240.00 x --
- Ask 13,250.00 x --
- Day's Range
13,070.00 - 13,490.00 - 52 Week Range
9,350.00 - 18,800.00 - Volume
186,510 - Avg. Volume
190,006 - Market Cap (intraday)
478.599B - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits. In addition, it offers CMO services comprising of drug product production, cell bank production, and drug substance production. Further, the company provides CRMO services, including cell line development, GMP production, validation, and the regulatory support; and operates facilities that manufacture protein-based therapeutics and antibodies. Additionally, it offers contract testing services that include lot release, stability, raw material, and method validation testing services. EuBiologics Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
www.eubiologics.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 206650.KQ
View MorePerformance Overview: 206650.KQ
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 206650.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 206650.KQ
View MoreValuation Measures
Market Cap
478.60B
Enterprise Value
430.85B
Trailing P/E
12.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.93
Price/Book (mrq)
3.24
Enterprise Value/Revenue
3.58
Enterprise Value/EBITDA
8.75
Financial Highlights
Profitability and Income Statement
Profit Margin
-20.01%
Return on Assets (ttm)
3.07%
Return on Equity (ttm)
-13.70%
Revenue (ttm)
69.37B
Net Income Avi to Common (ttm)
-13.88B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
11.49B
Total Debt/Equity (mrq)
14.10%
Levered Free Cash Flow (ttm)
-30.18B